Neonatal hyperparathyroidism and pamidronate therapy in an extremely premature infant.

Abstract	We describe the use of pamidronate to control marked hypercalcemia in an extremely premature infant with neonatal hyperparathyroidism that resulted from an inactivating mutation (R220W) of the calcium-sensing receptor. Despite improvement in bone mineralization and subsequent parathyroidectomy with normalization of the serum calcium level, the combination of chronic lung disease, osteomalacia, and poor thoracic cage growth ultimately proved fatal. Pamidronate therapy seems to be safe in the short-term and effective in helping control hypercalcemia even in the very premature infant, allowing for planned surgical intervention when it becomes feasible.
Authors	Lisa Fox, Joel Sadowsky, Kevin P Pringle, Alexa Kidd, Jean Murdoch, David E C Cole, Esko Wiltshire
Journal	Pediatrics (Pediatrics) Vol. 120 Issue 5 Pg. e1350-4 (Nov 2007) ISSN: 1098-4275 [Electronic] United States
PMID	17974727 (Publication Type: Case Reports, Journal Article)
Chemical References	Diphosphonates Pamidronate
Topics	Diphosphonates (therapeutic use) Fatal Outcome Female Humans Hyperparathyroidism (diagnostic imaging, drug therapy) Infant Infant, Newborn Infant, Premature Infant, Very Low Birth Weight Pamidronate Radiography

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!